We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Aptamer Group

Aptamer Group is a leading provider of Optimer® binders for use in therapeutics, diagnostics, bioprocessing and research. The Company strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer® technology.

Latest Content

Color-coded sample tubes arranged in laboratory racks.

Aptamer Develops Rapid Test for Bundibugyo Ebola

A new diagnostic program is developing synthetic binders to detect the Bundibugyo strain of Ebola, addressing the need for faster, more accurate testing during outbreaks.

Scoop in a bag of flour with fine white baking flour piled inside.

Rapid Folate Test Targets Food Fortification Programs

Researchers are developing a portable lateral flow test to measure folic acid in fortified foods, supporting food quality monitoring and helping reduce preventable birth defects in low-resource settings.

Scientist pipetting liquid into test tubes during a laboratory experiment.

New Radiopharma Platform Targets Stability Gains

Researchers are developing stable radioconjugates that show lower degradation rates, which may improve shelf life, and logistics, while enhancing targeted delivery of cancer therapies in future studies.

Scientist in a laboratory representing Aptamer Group’s Optimer binders partnership with a top pharmaceutical company.

Top-Five Pharmaceutical Company Expands Partnership With Aptamer for Multi-Target Optimer^® Development Program

Aptamer secures a £617K contract with a top-five pharmaceutical company to develop multi-target Optimer^® binders for therapeutic applications.

Two scientists collaborating in a lab using digital tools for drug discovery research.

Aptamer Expands Into Targeted Radiopharmaceuticals With Major Top 3 Pharma Contract

Aptamer inks £360K deal with a top pharma to develop Optimer® radiopharmaceuticals targeting cancer.

Medical illustration of human kidneys highlighting nephropathy and potential treatments.

Aptamer Signs Therapeutic Development Agreement With Invizius

Aptamer Group has signed a development agreement with Invizius to create Optimer^® binders targeting the complement system, implicated in autoimmune, fibrotic and inflammatory diseases.

Digital illustration promoting Aptamer’s innovative biomarker discovery service for drug and diagnostic research.

Aptamer Group^® Introduces Novel Biomarker Discovery Service

Aptamer Group unveils Optimer-based biomarker discovery service, enabling faster disease marker identification and validation.

Gloved hand holding test tube near DNA model representing gene therapy research.

Aptamer Group Identifies Novel Target To Enable Cell-Specific Gene Therapy for Liver Fibrosis

Aptamer validates targeted RNA delivery to liver fibrosis cells using its Optimer platform and a novel HSC marker.

Gloved hand holding test tube near DNA helix, symbolizing gene therapy research.

Aptamer Announces New Data at ASGCT

Aptamer Group presented new data on its Optimer therapeutic delivery vehicle for liver fibrosis, showing its potential for broad applicability in fibrotic diseases at the ASGCT 2025 Annual Meeting.

Scientists conducting research in a modern lab.

Optimer Licensing Agreements and Repeat Custom

Aptamer Group has secured two new development contracts and a licensing agreement to expand its Optimer platform’s applications in enzyme modulation and small molecule recognition.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter